On March 26, 2013, the US Food and Drug Administration approved ACIPHEX Sprinkle Delayed-Release Capsules 5mg and 10mg for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks.
Eisai president and CEO Lonnel Coats said: Eisai is committed to making Aciphex Sprinkle available to appropriate patients as part of our human health care (hhc) corporate mission of keeping patients medical needs at the forefront of all that we do.
Aciphex Sprinkle Delayed-Release Capsules 5mg and 10mg will be obtainable in US drugstores only with a prescription.
Eisai (TYO: 4523), a Japan-based pharmaceutical company, has received approval from the US FDA for ACIPHEX Sprinkle
as a 12-week gastroesophageal reflux disease therapy for use in children between one to eleven years of age.